Former Medtronic exec joins CSI to push peripheral artery disease therapy
This article was originally published in Clinica
Cardiovascular Systems (CSI), the developer of the Diamondback 360° orbital peripheral artery disease (PAD) system, has appointed Kevin Kenny to the new role of executive vice-president of sales and marketing. Prior to joining CSI, Mr Kenny spent nearly 10 years at Medtronic's Spine and Biologics division where he held various senior roles including vice-president of US sales and, most recently, executive consultant for special projects. Mr Kenny will apply his 20-plus years' sales experience to help push commercialisation of CSI's latest orbital PAD system, Stealth 360°, which was cleared by the FDA in March. The St Paul, Minnesota firm's PAD systems treat calcified and fibrotic plaque in arterial vessels throughout the leg within a few minutes.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.